Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study

Yunia Mayanja, Onesmus Kamacooko, Jane Frances Lunkuse, Vincent Muturi-Kioi, Allan Buzibye, Denis Omali, Kundai Chinyenze, Monica Kuteesa, Pontiano Kaleebu, Matt A Price, Yunia Mayanja, Onesmus Kamacooko, Jane Frances Lunkuse, Vincent Muturi-Kioi, Allan Buzibye, Denis Omali, Kundai Chinyenze, Monica Kuteesa, Pontiano Kaleebu, Matt A Price

Abstract

Introduction: Oral pre-exposure prophylaxis (PrEP) has been scaled up; however, data from real-world settings are limited. We studied oral PrEP preference, uptake, adherence and continuation among adolescent girls and young women (AGYW) vulnerable to HIV in sub-Saharan Africa.

Methods: We conducted a prospective cohort study among 14- to 24-year-old AGYW without HIV who were followed for 12 months in Kampala, Uganda. Within at least 14 days of enrolment, they received two education sessions, including demonstrations on five biomedical interventions that are; available (oral PrEP), will be available soon (long-acting injectable PrEP and anti-retroviral vaginal ring) and in development (PrEP implant and HIV vaccine). Information included mode and frequency of delivery, potential side effects and method availability. Volunteers ranked interventions, 1 = most preferred to 5 = least preferred. Oral PrEP was "preferred" if ranked among the top two choices. All were offered oral PrEP, and determinants of uptake assessed using Poisson regression with robust error variance. Adherence was assessed using plasma tenofovir levels and self-reports.

Results: Between January and October 2019, 532 volunteers were screened; 285 enrolled of whom 265 received two education sessions. Mean age was 20 years (SD±2.2), 92.8% reported paid sex, 20.4% reported ≥10 sexual partners in the past 3 months, 38.5% used hormonal contraceptives, 26.9% had chlamydia, gonorrhoea and/or active syphilis. Of 265 volunteers, 47.6% preferred oral PrEP. Willingness to take PrEP was 90.2%; however, uptake was 30.6% (n = 81). Following enrolment, 51.9% started PrEP on day 14 (same day PrEP offered), 20.9% within 30 days and 27.2% after 30 days. PrEP uptake was associated with more sexual partners in the past 3 months: 2-9 partners (aRR = 2.36, 95% CI: 1.20-4.63) and ≥10 partners (aRR 4.70, 95% CI 2.41-9.17); oral PrEP preference (aRR 1.53, 95% CI 1.08-2.19) and being separated (aRR 1.55, 95% CI 1.04-2.33). Of 100 samples from 49 volunteers during follow up, 19 had quantifiable tenofovir levels (>10 μg/L) of which only three were protective (>40 μg/L).

Conclusions: Half of AGYW preferred oral PrEP, uptake and adherence were low, uptake was associated with sexual behavioural risk and oral PrEP preference. Development of alternative biomedical products should be expedited to meet end-user preferences and, community delivery promoted during restricted movement.

Keywords: HIV prevention; adherence; adolescent girls and young women; pre-exposure prophylaxis; retention; sub-Saharan Africa.

Conflict of interest statement

The authors have no competing interests to declare.

© 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1
Figure 1
Retention of 265 AGYW who were offered PrEP (2019–2020).

References

    1. UNAIDS . Global AIDS update: seizing the moment, tackling entrenched inequalities to end epidemics. 2020.
    1. UNAIDS Fact Sheet . Global HIV Statistics. 2021.
    1. World Health Organisation . WHO implementation tool for pre‐exposure prophylaxis (PrEP) of HIV infection: module 12: adolescents and young adults. 2018.
    1. UNAIDS . Invest in HIV prevention. 2015.
    1. Abbai NS, Wand H, Ramjee GNS, Wand H, Ramjee G. Biological factors that place women at risk for HIV: evidence from a large‐scale clinical trial in Durban. BMC Women's Health. 2016;16(1):1–7.
    1. Cherenack EM, Jennifer R, Dow DE, Sikkema KJ. Sexual risk behaviors and menstrual and intravaginal practices among adolescent girls and young women in Tanzania: a cross‐sectional, school‐based study. Int J Sexual Health. 2020;32(4):394–407.
    1. Moise IK, de Joya E, Caplan B, Rodriguez VJ, Butts S, Chisembele M, et al. Adolescent and young adult couples' views of intravaginal practices: a qualitative analysis of a pilot study. Int J Womens Health. 2019;11:49–56.
    1. USAID . DREAMS: partnership to reduce HIV/AIDS in adolescent girls and young women. 2020.
    1. Dunbar MS, Kripke K, Haberer J, Castor D, Dalal S, Mukoma W, et al. Understanding and measuring uptake and coverage of oral pre‐exposure prophylaxis delivery among adolescent girls and young women in sub‐Saharan Africa. Sexual Health. 2018;15(6):513–21.
    1. Koss CA, Charlebois ED, Ayieko J, Kwarisiima D, Kabami J, Balzer LB, et al. Uptake, engagement, and adherence to pre‐exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72‐week interim analysis of observational data from the SEARCH study. Lancet HIV. 2020;7(4):e249–61.
    1. Mugwanya KK, Pintye J, Kinuthia J, Abuna F, Lagat H, Begnel ER, et al. Integrating preexposure prophylaxis delivery in routine family planning clinics: a feasibility programmatic evaluation in Kenya. PLoS Med. 2019;16(9):e1002885.
    1. Rousseau‐Jemwa E, Bekker LG, Bukusi E, Delany‐Moretlwe S, Omollo V, Travill D, et al. Early persistence of HIV pre‐exposure prophylaxis (PrEP) in African adolescent girls and young women (AGYW) from Kenya and South Africa. HIV Research for Prevention Conference 2018. Barcelona, Spain. 2018.
    1. Maseko B, Hill LM, Phanga T, Bhushan N, Vansia D, Kamtsendero L, et al. Perceptions of and interest in HIV pre‐exposure prophylaxis use among adolescent girls and young women in Lilongwe, Malawi. PLoS One. 2020;15(1):e0226062.
    1. Uganda National Council for Science and Technology . National guidelines for research involving humans as research participants. 2016.
    1. Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340–8.
    1. Greene GJ, Swann G, Fought AJ, Carballo‐Diéguez A, Hope TJ, Kiser PE, et al. Preferences for long‐acting pre‐exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among US men who have sex with men. AIDS Behav. 2017;21(5):1336–49.
    1. Huang W, Wu D, Ong JJ, Smith MK, Yang F, Fu H, et al. Prepared for PrEP: preferences for HIV pre‐exposure prophylaxis among Chinese men who have sex with men in an online national survey. BMC Infect Dis. 2019;19(1):1057.
    1. Eakle R, Weatherburn P, Bourne A. Understanding user perspectives of and preferences for oral PrEP for HIV prevention in the context of intervention scale‐up: a synthesis of evidence from sub‐Saharan Africa. J Int AIDS Soc. 2019;. 22:e25306.
    1. Sila J, Larsen AM, Kinuthia J, Owiti G, Abuna F, Kohler PK, et al. High awareness, yet low uptake, of pre‐exposure prophylaxis among adolescent girls and young women within family planning clinics in Kenya. AIDS Patient Care STDs. 2020;34(8):336–43.
    1. Ndase P, Celum C, Campbell J, Bukusi E, Kiarie J, Katabira E, et al. Successful discontinuation of the placebo arm and provision of an effective HIV prevention product after a positive interim efficacy result: the partners PrEP study experience. J Acquir Immune Defic Syndr. 2014;66(2):206–12.
    1. Gombe MM, Cakouros BE, Ncube G, Zwangobani N, Mareke P, Mkwamba A, et al. Key barriers and enablers associated with uptake and continuation of oral pre‐exposure prophylaxis (PrEP) in the public sector in Zimbabwe: qualitative perspectives of general population clients at high risk for HIV. PLoS One. 2020;15(1):e0227632.
    1. Koss CA, Ayieko J, Mwangwa F, Owaraganise A, Kwarisiima D, Balzer LB. Early adopters of HIV preexposure prophylaxis in a population‐based combination prevention study in rural Kenya and Uganda. Clin Infect Dis. 2018;67:1853–60.
    1. Celum C, Delany‐Moretlwe S, Hosek S, Dye B, Bekker L, Mgodi N, et al. Risk behavior, perception, and reasons for PrEP among young African women in HPTN 082. Conference on Retroviruses and Opportunistic Infections (CROI) 2018. Boston, Masachussetts. 2018.
    1. Price JT, Rosenberg NE, Vansia D, Phanga T, Bhushan NL, Maseko B, et al. Predictors of HIV, HIV risk perception, and HIV worry among adolescent girls and young women in Lilongwe, Malawi. J Acquir Immune Defic Syndr. 2018;. 77(1):53.
    1. Rousseau E, Bekker LG, Julies RF, Celum C, Morton J, Johnson R, et al. A community‐based mobile clinic model delivering PrEP for HIV prevention to adolescent girls and young women in Cape Town, South Africa. BMC Health Serv Res. 2021;21(1):888.
    1. Rousseau E, Katz AWK, O'Rourke S, Bekker LG, Delany‐Moretlwe S, Bukusi E, et al. Adolescent girls and young women's PrEP‐user journey during an implementation science study in South Africa and Kenya. PLoS One. 2021;16(10):e0258542.
    1. de Dieu Tapsoba J, Zangeneh SZ, Appelmans E, Pasalar S, Mori K, Peng L, et al. Persistence of oral pre‐exposure prophylaxis (PrEP) among adolescent girls and young women initiating PrEP for HIV prevention in Kenya. AIDS Care. 2021;33(6):712–20.
    1. Camlin CS, Koss CA, Getahun M, Owino L, Itiakorit H, Akatukwasa C, et al. Understanding demand for PrEP and early experiences of PrEP use among young adults in rural Kenya and Uganda: a qualitative study. AIDS Behav. 2020;24(7):2149–62.
    1. Celum CL, Delany‐Moretlwe S, Baeten JM, van der Straten A, Hosek S, Bukusi EA. HIV pre‐exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019;22:e25298.
    1. Kagaayi J, Batte J, Nakawooya H, Kigozi B, Nakigozi G, Strömdahl S. Uptake and retention on HIV pre‐exposure prophylaxis among key and priority populations in South‐Central Uganda. J Int AIDS Soc. 2020;23(8):e25588.
    1. King R, Muhanguzi E, Nakitto M, Mirembe M, Kasujja FX, Bagiire D, et al. Mobility study of young women who exchange sex for money or commodities using Google Maps and qualitative methods in Kampala, Uganda. BMJ Open. 2021;11(5):e043078.
    1. Matambanadzo P, Busza J, Mafaune H, Chinyanganya L, Machingura F, Ncube G, et al. “It went through the roof”: an observation study exploring the rise in PrEP uptake among Zimbabwean female sex workers in response to adaptations during Covid‐19. J Int AIDS Soc. 2021;24:e25813.
    1. Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6):e1003670.
    1. Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B. An HIV pre‐exposure prophylaxis demonstration project and safety study for young MSM. J Acquir Immune Defic Syndr. 2017;74(1):21–9.
    1. Wahome Wahome EW, Graham SM, Thiong'o AN, Mohamed K, Oduor T, Gichuru E, et al. PrEP uptake and adherence in relation to HIV‐1 incidence among Kenyan men who have sex with men. EClinicalMedicine. 2020;26:100541.
    1. Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir‐based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.
    1. Hillier HS, Bekker LG, Faesen SB, Hendrix CW, Riddler SA, Rasmussen S, et al. Trial design, enrollment status, demographics, and pharmacokinetics (PK) data from a blinded interim analysis from a phase 2a trial of Islatravir once monthly (QM) for HIV pre‐exposure prophylaxis (PrEP). J Int AIDS Soc. 2021;24(S1):13–4.
    1. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV‐1—infected patients. HIV Clin Trials. 2008;9(4):238–46.
    1. Brooks KM, Anderson PL. Pharmacologic‐based methods of adherence assessment in HIV prevention. Clin Pharmacol Ther. 2018;104(6):1056–9.
    1. Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, et al. Differences in cumulative exposure and adherence to tenofovir in the VOICE, iPrEx OLE, and PrEP demo studies as determined via hair concentrations. AIDS Res Hum Retroviruses. 2017;33(8):778–83.
    1. Falb K, Tanner S, Asghar K, Souidi S, Mierzwa S, Assazenew A, et al. Implementation of Audio‐Computer Assisted Self‐Interview (ACASI) among adolescent girls in humanitarian settings: feasibility, acceptability, and lessons learned. Conflict Health. 2016;10(1):1–8.
    1. Ndayizigiye M, Fawzi MC, Lively CT, Ware NC. Understanding low uptake of contraceptives in resource‐limited settings: a mixed‐methods study in rural Burundi. BMC Health Serv Res. 2017;17(1):209.
    1. Rominski Rominski SD, Morhe ESK, Maya E, Manu A, Dalton VK. Comparing women's contraceptive preferences with their choices in 5 urban family planning clinics in Ghana. Glob Health: Sci Pract. 2017;5(1):65–74.
    1. Fields EL, Fennell C, Wagner J, Schumacher C, Chandran A, Price A, et al. HIV risk factors associated with the pre‐exposure prophylaxis cascade among young and adult black men who have sex with men in Baltimore city. J Adolesc Health. 2019;64(2):S44.
    1. Hill LM, Maseko B, Chagomerana M, Hosseinipour MC, Bekker LG, Pettifor A, et al. HIV risk, risk perception, and PrEP interest among adolescent girls and young women in Lilongwe, Malawi: operationalizing the PrEP cascade. J Int AIDS Soc. 2020;23:e25502.
    1. Bjork J, Nyman U, Larsson A, Delanaye P, Pottel H. Estimation of the glomerular filtration rate in children and young adults by means of the CKD‐EPI equation with age‐adjusted creatinine values. Kidney Int. 2021;99(4):940–7.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit